about
Aurora kinases as prognostic biomarkers in ovarian carcinoma.Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinomaClinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifenAngiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancerCharacterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomasGraft-vs-host disease as a cause of enlargement of the epiglottis in an immunocompromised child.Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistryCommon non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association ConsortiumCrohn's disease limited to the appendix.The PTEN/NRF2 axis promotes human carcinogenesisContinuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer.Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomasThe NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.Angiogenesis and ovarian cancer.G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 AxisMolecular characterization of ovarian cancer by gene-expression profiling.Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues.Subclassification of the molecular types of breast cancer based on the expression of immunohistochemical markers and evolution.Primary Leiomyosarcoma of the Ovarian Vein: Case Report and Literature Review.DNA methylation signatures identify biologically distinct thyroid cancer subtypes.Tiling path genomic profiling of grade 3 invasive ductal breast cancers.Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.Role of placental barrier integrity in infection by Trypanosoma cruzi.Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions.New insights in beta-tubulin sequence analysis in non-small cell lung cancer.Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancerPrognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification.Adenomatoid tumors of the uterus: an analysis of 60 cases.mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.Cyclin D1 gene (CCND1) mutations in endometrial cancer.
P50
Q27851462-95405C49-FE1A-4F83-9C1B-4609B2BF96C3Q28188670-CE95DF53-9237-4064-AEBC-4EE60FC87BABQ28281218-35F19566-9E3A-4E8A-ABCE-45E367ADBBF3Q33396235-5A36D006-76D7-4166-9F88-44FEE9F31E45Q33472698-DC3C3271-471B-46A4-876A-47F3E964D656Q33579776-7C893DDA-0B5B-432D-9B58-7E10444C5138Q34197948-A2EC7F4C-B6AF-4756-BDF9-DF96B79BCC2BQ34214764-D79E1177-CF7B-4D1F-8FAA-3ECC2F0C1B67Q34231928-838F4E49-BFC9-4061-8094-3E51F64A6378Q34379032-E527EF32-5467-4E2C-A308-2BBA938264B7Q34469370-E00EBC78-C6B5-46C9-AFED-C7EBB8C05FC6Q34579435-0157C0E8-127C-47B2-8731-27E7C721D7ACQ34609696-4033BF3D-3E4B-4CBA-9D84-F5248D2C179BQ35984566-712C7FAE-CD18-438E-A6A8-9B1144D6971BQ36415308-75206B69-C17E-47B8-B879-4596AF0973C8Q37259213-51815DFB-BB94-4B3F-9EE8-49E39FAEA706Q37594336-D2E85AF3-C485-42EB-BC67-E0E3187A0323Q37602374-25CAAA9B-197B-43F9-892B-5BB7BCD9E8E7Q37604575-E14BF10C-1F3E-4D1A-A5C0-7CCAC1D1F2D1Q37741508-FCDBB128-09BD-4B25-908D-0A5ECDE8221AQ38415968-ED22D862-19DB-40B1-9F99-69E096AED9A2Q38692370-5D2C610B-D799-41F0-9404-5D102C69E01FQ39018449-4A946275-1913-4C66-9E94-E1E851F6195DQ39153033-9C6D9889-94F7-4344-B98B-EC013DF3946EQ39868704-E45A1FFE-04E2-491C-9611-AFC87BCD46C1Q39971722-83FC53E1-0FC3-42C3-8B7C-84293A89B27DQ40012189-49977FF3-52BE-44A1-B45E-9E11B3321CA3Q40205335-78EFC3E2-1B62-45C0-B00E-ACF5E8CE3916Q40303976-E4FB51A4-1880-454E-BB5A-EFCC3EA4B347Q40479877-ADA5E00D-338C-4805-974C-4D0FD4826034Q40568031-CE6651C3-E955-41AC-8398-35358A9D3668Q40578959-9134FF50-5AE6-44DD-BEEA-D73C9569FC85Q41134105-B86E7C87-3127-4DDA-A6E9-40A6944C6F48Q41495744-BFAC1ACF-8D61-46BE-829B-FFE191AA08ACQ42491999-C4AAD539-B17C-45E1-9EB7-A00501AAF360Q42509097-394DA732-B5DC-421A-8922-CED81914E93DQ43565064-5BD33C2A-3489-4236-B2F4-F995F41BDA65Q43848033-45A2F7AA-6670-4F54-8E7C-DA16BA8FF2FBQ44383595-28FACBA2-B555-40DF-B2A4-31E99432ACBBQ44573130-74BFA516-EA30-4EF1-BB58-EC6D31931626
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Hardisson
@ast
David Hardisson
@en
David Hardisson
@es
David Hardisson
@nl
David Hardisson
@sl
type
label
David Hardisson
@ast
David Hardisson
@en
David Hardisson
@es
David Hardisson
@nl
David Hardisson
@sl
prefLabel
David Hardisson
@ast
David Hardisson
@en
David Hardisson
@es
David Hardisson
@nl
David Hardisson
@sl
P1053
E-2832-2010
P106
P21
P2798
P31
P496
0000-0002-2183-3699